Genix Pharmaceut - GENPF STOCK NEWS

Welcome to our dedicated page for Genix Pharmaceut news (Ticker: GENPF), a resource for investors and traders seeking the latest updates and insights on Genix Pharmaceut stock.

Genix Pharmaceuticals Corporation (GENPF) is a pioneering player in the ophthalmic drugs industry. Specializing in novel and generic products, the company excels in research, development, and distribution of evidence-based healthcare solutions. With a strong focus on proprietary OTC nutraceuticals and single molecule generic drugs, Genix aims to deliver consistent and effective results across various therapeutic areas. The company's global presence extends to markets in Canada and beyond, catering to the health needs of mainstream consumers. Through ongoing R&D efforts, Genix remains committed to innovation and excellence in the pharmaceutical sector.

02/06/2024 01:29 PM

News

Genix Announces TSX-V Approval of Warrant Amendments

Rhea-AI Summary

Genix Pharmaceuticals Corporation (GENX) has received approval from the TSX Venture Exchange to amend the exercise price and warrant accelerator terms, as well as extend the expiry dates of previously issued warrants. The exercise price of the warrants will be reduced from $0.30 to $0.15 per warrant share, and the accelerator repricing will be adjusted from $0.50 to $0.25 per share. Additionally, 2,101,612 warrants will be extended to July 24, 2025, and 1,253,333 warrants will be extended to August 13, 2025. The company acknowledges clerical errors in previous press releases and apologizes for any inconvenience caused.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Genix Announces Warrant Repricing and Seeks Extension

Rhea-AI Summary

Genix Pharmaceuticals Corporation (GENPF) has applied to the TSX Venture Exchange to amend the exercise price, warrant accelerator terms, and extend the expiry date of previously issued warrants. The proposed amendments include reducing the exercise price of the warrants, subjecting them to an accelerator repricing, and extending the expiry dates of certain warrants. The amendments are subject to the consent of all warrant holders and the approval of the TSX Venture Exchange.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Genix Announces AGM Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Genix Pharmaceut (GENPF)?

The current stock price of Genix Pharmaceut (GENPF) is $0.04 as of February 7, 2025.

What is the market cap of Genix Pharmaceut (GENPF)?

The market cap of Genix Pharmaceut (GENPF) is approximately 2.0M.

What is Genix Pharmaceuticals Corporation known for?

Genix is a leading player in the ophthalmic drugs industry, specializing in novel and generic healthcare products.

Where does Genix market and sell its products?

Genix markets its portfolio of ophthalmic drugs globally and nutraceutical products in North America and select countries.

What is the focus of Genix's research and development efforts?

Genix focuses on developing evidence-based proprietary OTC nutraceuticals and single molecule generic drugs with proven therapeutic benefits.

Who leads Genix Pharmaceuticals Corporation?

Mr. Mahmoud Aziz serves as the President and Director of Genix Pharmaceuticals Corporation.

How can I contact Genix Pharmaceuticals Corporation for more information?

For more information, you can reach out to Kevin Bottomley, Director, at +1.604.609.6199 or kbottomley@genixpharm.com.

Genix Pharmaceut

OTC:GENPF

GENPF Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

GENPF Stock Data

Market Cap 1.97M

Float 47.83M

Insiders Ownership 43.35%

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Website Link

Country Canada

City Vancouver